Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Urological cancer

CHAARTED/GETUG 12—docetaxel in non-castrate prostate cancers

In two recent phase III trials, investigators evaluated the addition of docetaxel to androgen-deprivation therapy for non-castrate prostate cancer. On the basis of the CHAARTED-trial findings, we can firmly conclude that this combination can be used in the metastatic setting. The results of the GETUG 12 trial are less informative, although some benefit for patients with high-risk localized prostate cancer was demonstrated.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Timeline of the GETUG 12 trial.4

References

  1. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).

    Article  CAS  Google Scholar 

  2. Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513–1520 (2004).

    Article  CAS  Google Scholar 

  3. Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737–746 (2015).

    Article  CAS  Google Scholar 

  4. Fizazi, K. et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol. 16, 787–794 (2015).

    Article  CAS  Google Scholar 

  5. Tangen, C. M. et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J. Urol. 188, 1164–1169 (2012).

    Article  Google Scholar 

  6. James, N. D. et al. Docetaxel and/or zoledronic acid for hormone-naive prostate cancer: first overall survival results from STAMPEDE (NCT00268476) [abstract]. J. Clin. Oncol. 33 (Suppl.), a5001 (2015).

    Article  Google Scholar 

  7. Gravis, G. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 14, 149–158 (2013).

    Article  CAS  Google Scholar 

  8. Chang, A. J., Autio, K. A., Roach, M. 3rd & Scher, H. I. High-risk prostate cancer-classification and therapy. Nat. Rev. Clin. Oncol. 11, 308–323 (2014).

    Article  Google Scholar 

  9. Antonarakis, E. S. et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 109, 32–39 (2011).

    Article  Google Scholar 

  10. Heidenreich, A. et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 65, 467–479 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Howard I. Scher.

Ethics declarations

Competing interests

H.I.S. has received reimbursement of travel and has acted as a consultant (noncompensated) for Sanofi. M.Y.T. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Teo, M., Scher, H. CHAARTED/GETUG 12—docetaxel in non-castrate prostate cancers. Nat Rev Clin Oncol 12, 687–688 (2015). https://doi.org/10.1038/nrclinonc.2015.192

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2015.192

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing